Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

• Status: Unknown status
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Collaborator: Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• 1. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology;

• 2. Pancreatic cancer after radical resection;

• 3. Eastern Cooperative Oncology Group Performance Status less than 2;

• 4. Without radiotherapy or neoadjuvant chemotherapy;

• 5. The man or the gestation and lactation women Age between 18 to 80 years old;

• 6. Bone marrow functioned well: ANC more than 1.5*10^9/ L, PLT more than 100*10^9/LHgb more than 9 g/dL;

• 7. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN, TBIL less than 1.5 ULN;

• 8. PT and PPT are in normal ranges;

• 9. Three months prior to clinical research did not receive any other clinical research trials;

• 10. patients are voluntary, and willing to sign informed consent.

Exclusion Criteria:

• 1. Patients with other malignant tumors in the past five years;

• 2. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment;

• 3. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection;

• 4. Known allergy to any kind of component of study drugs;

• 5. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis);

• 6. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy;

• 7. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements;

• 8. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.